Soleno Therapeutics, Inc. (SLNO)
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on rare diseases, with its lead candidate targeting Prader-Willi syndrome (PWS), a complex genetic disorder. The company’s primary product, diazoxide choline controlled-release (DCCR), is an oral therapy designed to address the unmet needs in PWS by reducing hyperphagia and improving metabolic outcomes. It aims to provide patients with better quality of life through innovative treatments.
The company’s growth is driven by the large unmet need in rare disease management and the promising clinical trial data supporting DCCR. With orphan drug designation and potential regulatory exclusivity, Soleno is strategically positioned in the rare disease space. The market opportunity for PWS is significant, with few effective treatments currently available. Positive trial results have sparked interest among investors and clinicians alike.
Soleno is working toward FDA approval for DCCR and is expanding its research into related indications. As awareness and diagnosis of PWS increase, the addressable market could grow. Soleno’s focused pipeline and patient-first approach make it a compelling player in the biotech field. The company is actively engaging with regulators, caregivers, and the medical community to drive adoption and commercial readiness. Chart
